Business Context and Reporting Period
Company: OXIS International, Inc. (Note: Input metadata referenced "GT Biopharma," but the filing text identifies the registrant as OXIS International, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
OXIS International, Inc. is a biotechnology company focused on the research, development, and sale of products designed to counteract oxidative stress and inflammation. The company pivoted from its historical business of selling clinical and research assay products (sold in 2008) to a new strategy centered on commercializing L-Ergothioneine ("ERGO") based nutraceuticals and cosmeceuticals. In December 2010, the company initiated a direct mail test marketing program for its first ERGO-based product, "ErgoFlex," a dietary supplement for joint pain.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $11,000 | $48,000 |
| Cost of Product Revenue | $65,000 | $50,000 |
| Gross Profit | ($54,000) | ($2,000) |
| Net Loss | ($2,995,000) | ($2,246,000) |
| Accumulated Deficit | ($80,095,000) | ($77,100,000) |
| Cash and Cash Equivalents | $54,000 | $1,293,000 |
| Working Capital Deficit | ($5,517,000) | ($5,566,000) |
| Total Liabilities | $5,654,000 | $7,108,000 |
Debt and Liquidity: The company holds a working capital deficit of approximately $5.5 million. Cash on hand ($54,000) is sufficient to fund administrative expenses for only a few months. The company has outstanding convertible debentures, demand notes, and warrant liabilities. A $750,000 revolving line of credit for inventory purchases was established with Gemini Pharmaceuticals, Inc. in October 2010.
Material Changes vs. Prior Period
- Revenue Decline: Product revenues decreased by 77.1% (from $48,000 to $11,000) as the company ceased marketing the previous product (Ergo-Plex) and was in the early stages of launching ErgoFlex.
- Increased Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by approximately 97% (from $1.15 million to $2.26 million) due to the hiring of new officers and employees in March 2010 to support the new business strategy.
- Research and Development: R&D expenses were $179,000 in 2010 compared to $0 in 2009, driven by testing and certification for the ErgoFlex product.
- Interest Expense Reduction: Interest expense decreased from $1.14 million to $513,000, primarily due to the conversion of $1.74 million of debentures into equity during 2010.
- Capital Structure: The company issued 1.67 million shares of Series I Convertible Preferred Stock in November 2010 for $250,000 and converted significant debt obligations into common stock.
Guidance, Outlook, and Risks
Outlook and Strategy: Management plans to aggressively pursue the commercial exploitation of ERGO. The primary marketing initiative is a joint venture formed in March 2011 with engage:BDR, Inc., for online marketing. The company intends to contribute up to $1.5 million to this joint venture in its first year. Additional ERGO-based products are planned for release in 2011 and 2012.
Going Concern: The filing includes a "substantial doubt" regarding the company's ability to continue as a going concern. The company has an accumulated deficit of over $80 million and requires additional capital to fund operations and the joint venture. There is no assurance that financing will be available.
Key Risks:
- Capital Needs: The company lacks sufficient cash to fund operations beyond a few months and must raise additional debt or equity, which may result in significant dilution.
- Joint Venture Dependency: Future success is heavily dependent on the engage:BDR joint venture, which requires a $1.5 million capital contribution the company currently does not possess.
- Regulatory: Products are subject to FDA and FTC regulations; failure to comply could result in penalties or product recalls.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of December 31, 2010, citing a lack of segregation of duties and risks of executive override due to a small staff.
Investor Verification Checklist
- Capital Sufficiency: Verify if the company has secured the $1.5 million required for the engage:BDR joint venture and additional funding for operations.
- Revenue Realization: Monitor the actual sales performance of ErgoFlex and subsequent product launches to determine if the pivot to nutraceuticals generates sustainable revenue.
- Dilution Impact: Assess the potential dilution from outstanding options, warrants, and convertible debentures, which could result in the issuance of over 400 million additional shares.
- Debt Obligations: Review the status of the $2 million 0% Convertible Debentures due September 30, 2011, and the $750,000 Gemini credit facility.
- Internal Controls: Confirm if the company has remediated the material weaknesses in internal controls identified in the 2010 filing.